138 related articles for article (PubMed ID: 38197567)
1. Droplet digital PCR for sensitive relapse detection in acute myeloid leukaemia patients transplanted by reduced intensity conditioning.
Gronlund JK; Veigaard C; Juhl-Christensen C; Skou AS; Melsvik D; Ommen HB
Eur J Haematol; 2024 Apr; 112(4):601-610. PubMed ID: 38197567
[TBL] [Abstract][Full Text] [Related]
2. Multi-gene measurable residual disease assessed by digital polymerase chain reaction has clinical and biological utility in acute myeloid leukemia patients receiving venetoclax/azacitidine.
Winters AC; Minhajuddin M; Stevens BM; Major A; Bosma G; Abbott D; Miltgen N; Yuan J; Treece AL; Siegele BJ; Ewalt MD; Gutman JA; Jordan CT; Pollyea DA
Haematologica; 2024 Jun; 109(6):1766-1778. PubMed ID: 38105738
[TBL] [Abstract][Full Text] [Related]
3. Droplet digital PCR: An effective method for monitoring and prognostic evaluation of minimal residual disease in JMML.
Mao S; Lin Y; Qin X; Miao Y; Luo C; Luo C; Wang J; Huang X; Zhu H; Lai J; Chen J
Br J Haematol; 2024 Jun; 204(6):2332-2341. PubMed ID: 38622924
[TBL] [Abstract][Full Text] [Related]
4. Comparison of RNA- and DNA-based methods for measurable residual disease analysis in NPM1-mutated acute myeloid leukemia.
Pettersson L; Johansson Alm S; Almstedt A; Chen Y; Orrsjö G; Shah-Barkhordar G; Zhou L; Kotarsky H; Vidovic K; Asp J; Lazarevic V; Saal LH; Fogelstrand L; Ehinger M
Int J Lab Hematol; 2021 Aug; 43(4):664-674. PubMed ID: 34053184
[TBL] [Abstract][Full Text] [Related]
5. Detection of NPM1 Mutations in Acute Myeloid Leukemia by using Drop-Off Droplet Digital PCR and its Clinical Application.
Jin Y; Xu ZJ; Yu D; Xia PH; Yao DM; Yuan Q; Li T; Xiang HL; Ma JC; Wen XM; Lin J; Qian J
Clin Lab; 2023 Nov; 69(11):. PubMed ID: 37948486
[TBL] [Abstract][Full Text] [Related]
6. Multi-target measurable residual disease assessed by error-corrected sequencing in patients with acute myeloid leukemia: An ALFA study.
Hirsch P; Lambert J; Bucci M; Deswarte C; Boudry A; Lambert J; Fenwarth L; Micol JB; Terré C; Celli-Lebras K; Thomas X; Dombret H; Duployez N; Preudhomme C; Itzykson R; Delhommeau F
Blood Cancer J; 2024 Jun; 14(1):97. PubMed ID: 38871702
[TBL] [Abstract][Full Text] [Related]
7. Digital droplet PCR-based absolute quantification of pre-transplant NPM1 mutation burden predicts relapse in acute myeloid leukemia patients.
Bill M; Grimm J; Jentzsch M; Kloss L; Goldmann K; Schulz J; Beinicke S; Häntschel J; Cross M; Vucinic V; Pönisch W; Behre G; Franke GN; Lange T; Niederwieser D; Schwind S
Ann Hematol; 2018 Oct; 97(10):1757-1765. PubMed ID: 29785446
[TBL] [Abstract][Full Text] [Related]
8. Transferring measurable residual disease measurement in pediatric acute lymphoblastic leukemia from quantitative real-time PCR to digital droplet PCR.
Luib L; Kreyenberg H; Michaelis S; Handgretinger R; Mezger M
Pediatr Transplant; 2023 Jun; 27(4):e14483. PubMed ID: 36750990
[TBL] [Abstract][Full Text] [Related]
9. [Detection of NPM1 Mutation in Acute Myeloid Leukemia by Droplet Digital PCR and Its Clinical Application Value].
Jin Y; Wang SS; Xia PH; Yuan Q; Xiao GF; Lin J; Leng JY; Ma YJ; Qian J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Jun; 30(3):653-658. PubMed ID: 35680787
[TBL] [Abstract][Full Text] [Related]
10. Applicability of droplet digital polymerase chain reaction for minimal residual disease monitoring in Philadelphia-positive acute lymphoblastic leukaemia.
Ansuinelli M; Della Starza I; Lauretti A; Elia L; Siravo V; Messina M; De Novi LA; Taherinasab A; Canichella M; Guarini A; Foà R; Chiaretti S
Hematol Oncol; 2021 Dec; 39(5):680-686. PubMed ID: 34402088
[TBL] [Abstract][Full Text] [Related]
11. Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial.
Platzbecker U; Middeke JM; Sockel K; Herbst R; Wolf D; Baldus CD; Oelschlägel U; Mütherig A; Fransecky L; Noppeney R; Bug G; Götze KS; Krämer A; Bochtler T; Stelljes M; Groth C; Schubert A; Mende M; Stölzel F; Borkmann C; Kubasch AS; von Bonin M; Serve H; Hänel M; Dührsen U; Schetelig J; Röllig C; Kramer M; Ehninger G; Bornhäuser M; Thiede C
Lancet Oncol; 2018 Dec; 19(12):1668-1679. PubMed ID: 30442503
[TBL] [Abstract][Full Text] [Related]
12. Prognostic Impact of Blood
Jentzsch M; Bill M; Grimm J; Schulz J; Beinicke S; Häntschel J; Goldmann K; Pönisch W; Franke GN; Vucinic V; Cross M; Behre G; Lange T; Niederwieser D; Schwind S
Hemasphere; 2019 Feb; 3(1):e167. PubMed ID: 31723806
[TBL] [Abstract][Full Text] [Related]
13. Post-Transplantation Day +100 Minimal Residual Disease Detection Rather Than Mixed Chimerism Predicts Relapses after Allogeneic Stem Cell Transplantation for Intermediate-Risk Acute Myelogenous Leukemia Patients Undergoing Transplantation in Complete Remission.
Klyuchnikov E; Badbaran A; Massoud R; Fritzsche-Friedland U; Freiberger P; Ayuk F; Wolschke C; Bacher U; Kröger N
Transplant Cell Ther; 2022 Jul; 28(7):374.e1-374.e9. PubMed ID: 35429661
[TBL] [Abstract][Full Text] [Related]
14. Minimal/Measurable Residual Disease Monitoring in
Forghieri F; Comoli P; Marasca R; Potenza L; Luppi M
Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30404199
[TBL] [Abstract][Full Text] [Related]
15. Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation.
Mulé MP; Mannis GN; Wood BL; Radich JP; Hwang J; Ramos NR; Andreadis C; Damon L; Logan AC; Martin TG; Hourigan CS
Biol Blood Marrow Transplant; 2016 Nov; 22(11):1974-1982. PubMed ID: 27544285
[TBL] [Abstract][Full Text] [Related]
16. Droplet digital PCR for the simultaneous analysis of minimal residual disease and hematopoietic chimerism after allogeneic cell transplantation.
Waterhouse M; Pfeifer D; Duque-Afonso J; Follo M; Duyster J; Depner M; Bertz H; Finke J
Clin Chem Lab Med; 2019 Apr; 57(5):641-647. PubMed ID: 30457973
[TBL] [Abstract][Full Text] [Related]
17. Measurable residual disease detected by flow cytometry independently predicts prognoses of NPM1-mutated acute myeloid leukemia.
Zhang YW; Su L; Tan YH; Lin H; Liu XL; Liu QJ; Sun JN; Zhang M; Du YZ; Song F; Han W; Gao SJ
Ann Hematol; 2023 Feb; 102(2):337-347. PubMed ID: 36378304
[TBL] [Abstract][Full Text] [Related]
18. NPM1 mutation is a stable marker for minimal residual disease monitoring in acute myeloid leukaemia patients with increased sensitivity compared to WT1 expression.
Kristensen T; Møller MB; Friis L; Bergmann OJ; Preiss B
Eur J Haematol; 2011 Nov; 87(5):400-8. PubMed ID: 21707751
[TBL] [Abstract][Full Text] [Related]
19. Pre-transplant Quantitative Determination of NPM1 Mutation Significantly Predicts Outcome of AIlogeneic Hematopoietic Stem Cell Transplantation in Patients with Normal Karyotype AML in Complete Remission.
Karas M; Steinerova K; Lysak D; Hrabetova M; Jungova A; Sramek J; Jindra P; Polivka J; Holubec L
Anticancer Res; 2016 Oct; 36(10):5487-5498. PubMed ID: 27798920
[TBL] [Abstract][Full Text] [Related]
20. Peripheral blood marker of residual acute leukemia after hematopoietic cell transplantation using multi-plex digital droplet PCR.
Stanojevic M; Grant M; Vesely SK; Knoblach S; Kanakry CG; Nazarian J; Panditharatna E; Panchapakesan K; Gress RE; Holter-Chakrabarty J; Williams KM
Front Immunol; 2022; 13():999298. PubMed ID: 36248870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
